Identification_NN
of_IN
a_DT
human_JJ
LIM-Hox_NN
gene_NN
,_,
hLH-2_NN
,_,
aberrantly_RB
expressed_VBD
in_IN
chronic_JJ
myelogenous_JJ
leukemia_NN
and_CC
located_JJ
on_IN
9q33-34_NN
.1_CD
._.

We_PRP
describe_VBP
the_DT
isolation_NN
of_IN
human_JJ
LH-2_NN
,_,
a_DT
putative_JJ
transcription_NN
factor_NN
containing_VBG
two_CD
cysteine-rich_JJ
regions_NNS
-LRB-_-LRB-
LIM_NN
domains_NNS
-RRB-_-RRB-
and_CC
a_DT
homeobox_NN
-LRB-_-LRB-
Hox_NN
-RRB-_-RRB-
DNA-binding_JJ
domain_NN
._.

High_JJ
levels_NNS
of_IN
hLH-2_NN
expression_NN
were_VBD
observed_VBN
in_IN
all_DT
cases_NNS
of_IN
chronic_JJ
myelogenous_JJ
leukemia_NN
-LRB-_-LRB-
CML_NN
-RRB-_-RRB-
tested_VBN
,_,
regardless_RB
of_IN
disease_NN
status_NN
._.

hLH-2_NN
was_VBD
mapped_VBN
to_TO
chromosome_NN
9Q33-34_NN
.1_CD
,_,
in_IN
the_DT
same_JJ
region_NN
as_IN
the_DT
reciprocal_JJ
translocation_NN
that_WDT
creates_VBZ
the_DT
BCR-ABL_NN
chimera_NN
of_IN
the_DT
Philadelphia_NN
chromosome_NN
-LRB-_-LRB-
Ph_NN
'_''
-RRB-_-RRB-
,_,
the_DT
hallmark_NN
of_IN
CML_NN
;_:
hLH-2_NN
was_VBD
retained_VBN
on_IN
the_DT
derivative_NN
9_CD
chromosome_NN
and_CC
is_VBZ
therefore_RB
centromeric_JJ
of_IN
c-ABL_NN
._.

The_DT
proximity_NN
of_IN
hLH-2_NN
to_TO
the_DT
breakpoint_NN
on_IN
chromosome_NN
9_CD
raises_VBZ
the_DT
possibility_NN
of_IN
cis-activation_NN
by_IN
the_DT
t_NN
-LRB-_-LRB-
9_CD
;_:
22_CD
-RRB-_-RRB-
-LRB-_-LRB-
q34_NN
;_:
q11_NN
-RRB-_-RRB-
translocation_NN
._.

In_IN
addition_NN
to_TO
finding_NN
hLH-2_NN
expression_NN
in_IN
all_DT
cases_NNS
of_IN
CML_NN
,_,
expression_NN
was_VBD
observed_VBN
in_IN
lymphoid_JJ
malignancies_NNS
and_CC
myeloid_JJ
cell_NN
lines_NNS
,_,
but_CC
not_RB
in_IN
primary_JJ
cases_NNS
of_IN
acute_JJ
myelogenous_JJ
leukemia_NN
._.

The_DT
role_NN
of_IN
hLH-2_NN
in_IN
the_DT
development_NN
or_CC
progression_NN
of_IN
leukemia_NN
is_VBZ
not_RB
known_VBN
._.

However_RB
,_,
hLH-2_NN
may_MD
prove_VB
useful_JJ
as_IN
a_DT
marker_NN
of_IN
CML_NN
for_IN
monitoring_VBG
residual_JJ
disease_NN
._.

